Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumovax II new-process versus current-process polysaccharides in healthy adults
2005-002789-12Phase 4Completed
- Sponsor
- Sanofi Pasteur MSD S.N.C
- Start
- Aug 2005
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of 23-valent pneumococcal polysaccharide vaccine in invasive pneumococcal disease (IPD) (2 arms), sponsored by Sanofi Pasteur MSD S.N.C. Primary endpoints: One-month post-vaccination geometric mean titre of antibody to pneumococcal serotype 3 and One-month post-vaccination geometric mean titre of antibody to pneumococcal serotype 8. Started Aug 2005; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on 2005-002789-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002789-12.